MediciNova (NASDAQ:MNOV) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV) in a research report released on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Stock Performance

Shares of NASDAQ:MNOV opened at $2.10 on Friday. The company has a market capitalization of $103.00 million, a PE ratio of -12.24 and a beta of 0.72. MediciNova has a 52 week low of $1.12 and a 52 week high of $2.16. The company’s fifty day moving average is $1.49 and its 200-day moving average is $1.43.

MediciNova (NASDAQ:MNOV) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts forecast that MediciNova will post -0.23 EPS for the current year.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.